AK
Akari Therapeutics, Plc
AKTX · NASDAQ
$11.77 +8.78% (+$0.95)
1M +63.86%
Market Cap $13.0M
P/E Ratio -
Div. Yield -
ROE 147.45%
Bulios Fair Price
$17.04
44.8% upside
Current Price
$11.77
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AKTX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.70x
EV/EBITDA N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 151.02%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 147.45%
ROA 80.16%
Asset turnover 0.00x
Debt
49 /100
Moderate Current ratio 0.60x
Int. coverage -32.09x
Debt/Equity 0.04x
Stability
43 /100
Moderate EPS volatility 33.66%
Profitable years 0
Beta 1.39x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AKTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Abizer Gaslightwala
Employees
6
Headquarters
Tampa
Upcoming events
04 DEC
Earnings
Upcoming earnings report